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Abstract
Background Macular choroidal neovascularization (CNV)
is one of the most vision-threatening complications of
myopia, which can lead to severe vision loss. The purpose
of this study was to evaluate the safety and efficacy of
intravitreal ranibizumab in the treatment of myopic CNV.
Methods We conducted a prospective, consecutive, inter-
ventional study of patients with subfoveal or juxtafoveal
CNV secondary to pathologic myopia (PM) treated with
intravitreal injection of ranibizumab in the Jules Gonin
University Eye Hospital from June 2006 to February 2008.
Best-corrected visual acuity (BCVA), optical coherence
tomography (OCT), and fluorescein angiography (FA) were
performed at baseline and monthly for all patients.
Indications for retreatment were loss in BCVA associated
either with persistent leakage from CNV shown on FA, and/
or evidence of CNV activity on OCT.
Results The study included 14 eyes of 14 patients. The
mean spherical equivalent refractive error was −12.5
(range, −8.0 D to −16.0 D). Mean time of follow-up was
8.4 months (range from 3 to 16 months, SD: 3). The mean
number of intravitreal injections administered for each
patient was 2.36 (SD 1.5). The mean initial visual acuity
(VA) was 0.19 decimal equivalent (logMAR: 0.71, SD:
0.3). A statistically significant improvement to a mean VA
of 0.48 decimal equivalent (log-MAR:0.32, SD: 0.25) was
demonstrated at the final follow-up. VA improved by a
mean of 3.86 (SD 2.74) lines. Nine patients (64%)
demonstrated a gain of 3 or more lines. Mean central
macular thickness (CMT) measured with OCT was 304 μm
(SD: 39) at the baseline, and was reduced significantly at the
final follow-up to 153 μm (SD: 23). Average CMT reduction
was 170 μm (SD: 57). No injection complications or drug-
related side effects were noted during the follow-up period.
Conclusions In this small series of eyes with limited
follow-up, intravitreal ranibizumab was a safe and effective
treatment for CNV secondary to PM, resulting in functional
and anatomic improvements.
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Introduction
Macular choroidal neovascularization (CNV) is one of the
most vision-threatening complications of myopia [1–3]. It
is also the most common cause of CNV in young
individuals, accounting for almost 60% of CNV in patients
younger than 50 years of age [4]. CNV as a complication of
pathologic myopia (PM) can be devastating, leading to
severe vision loss [1].
Photodynamic therapy (PDT) with verteporfin (Visu-
dyne; Novartis AG, Basel, Switzerland) is currently the
only approved treatment by the European Agency for the
Evaluation of Medicinal Products and the US Food and
Drug Administration (FDA) for subfoveal CNV related to
PM that has shown stabilization of vision compared with
placebo. However, the primary outcome was not statisti-
cally significantly in favor of verteporfin therapy at 2-year
follow-up [5].
Several other treatments have been assessed, including
thermal laser photocoagulation [6], macular translocation
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[7, 8], surgical removal of CNV [9], radiotherapy [10],
indocyanine green mediated photothrombosis [11, 12], and
combined PDT and intravitreal triamcinolone injection [13,
14]. However, the beneficial effects of these treatments are
questionable, primarily because of the risk of severe
complications or poor long-term results.
The factors that stimulate pathologic neovascularization
are incompletely understood, but vascular endothelial
growth factor-A (VEGF-A), which is a diffusible cytokine
that promotes angiogenesis and vascular permeability, has
been implicated as an important factor promoting neo-
vascularization [15, 16]. Two isoforms have been detected
in choroidal neovascular lesions [15].
Ranibizumab (Lucentis®, Novartis, Basel, Switzerland)
is a specific, affinity-mature fragment of a recombinant,
humanized IgG1 monoclonal antibody that neutralizes all
active forms of VEGF-A. It has been found to be effective
in the treatment of exudative age-related macular degener-
ation (AMD), demonstrating encouraging signs of biologic
activity, with acceptable safety [17].
Several studies have reported promising short-term
results with off-label use of the intravitreal anti-VEGF drug
bevacizumab (Avastin™, Genentech, South San Francisco,
CA, USA) for the treatment of CNV in PM [18–25]. There
are no published reports regarding the use of ranibizumab
for the treatment of CNV in PM.
Ranibizumab has several advantages over bevacizumab.
In addition to its smaller size, ranibizumab is genetically
engineered to have a greater affinity for VEGF, and is
formulated for intraocular use; more of the drug may
therefore penetrate all layers of the retina [26, 27]. It has
been hypothesized that the efficacy of intravitreal ranibizu-
mab in PM might be better than the results achieved with
intravitreal bevacizumab [28].
This study evaluated the safety and efficacy of intravitreal
ranibizumab (Lucentis®) as treatment for CNV due to PM.
Patients and methods
Patient selection
This was a prospective, consecutive, interventional study of
patients with subfoveal or juxtafoveal CNV secondary to
PM treated with intravitreal injection of ranibizumab in the
Jules Gonin University Eye Hospital from June 2006 to
February 2008.
Inclusion criteria were (1) a minimum spherical equiv-
alent refractive error of 6.0 diopters (D) and retinal signs of
PM, (2) a minimum of 3 months of follow-up, (3) best-
corrected visual acuity (BCVA) of 0.05 or better (decimal
equivalent), and (4) evidence of an active CNVon the basis
of the presence of leakage on fluorescein angiography (FA)
and/or intraretinal or subretinal fluid on optical coherence
tomography (OCT).
Patients were excluded from the study if they presented
features of any condition other than PM associated with
choroidal neovascularization that could suggest a different
etiology such as age-related macular degeneration. Further-
more, patients were excluded who presented any significant
ocular disease (other than CNV) that could compromise
vision in the studied eye. Previous PDT treatment was not
an exclusion criterion, on condition that it had been
administered at least 6 months before Lucentis® treatment.
Examination
Patient age, sex, affected eye, spherical equivalent refrac-
tion, and any previous treatment administered were
recorded.
The patients were followed every month. Both initial
ophthalmic examination and each follow-up included: (1)
evaluation of best-corrected distant and near VA using an
EDTRS chart and a nearpoint Snellen acuity card at 40 cm
respectively, (2) a fundus exam with dilated pupils, (3)
fundus photography, (4) digital FA, and (5) an evaluation of
retinal architecture and measurement of foveal thickness
using the OCT Stratus (Carl Zeiss Meditec, Inc.). Any
ocular or systemic adverse events were also recorded.
Indications for retreatment were persistent leakage from
CNV shown on FA and/or presence of intraretinal or
subretinal fluid shown on OCT. An informed consent was
obtained from all patients after a thorough discussion
before each injection.
Surgical procedure
All injections were performed by the same surgeon (LK)
using the same technique. Ranibizumab 0.5 mg (0.05 ml)
was administered by intravitreal injection under sterile
conditions in the operating theatre. Before injection,
tetracaine 0.5% was applied topically. Povidone iodine
was applied to eyelid margins, eyelashes, and conjunctival
surface, and a lid speculum was placed. An additional drop
of povidone iodine was applied to site of injection. Using a
30-gauge needle, 0.05 ml ranibizumab was injected 3.5–
4.0 mm posterior to the corneal limbus into the vitreous
cavity. The injection site was compressed with a cotton
swab to avoid reflux when the needle was removed.
Postoperatively, a topical antibiotic (ofloxacin) was admin-
istered three times daily for 7 days.
Statistical analysis
The statistical analysis focused on the evaluation of the
change in BCVA and the foveal thickness measured by
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OCT before treatment and at the final follow-up. Addition-
ally, the absence or persistence of leakage on FA at the final
follow-up was evaluated. BCVA values were converted to
logarithm of the minimum angle of resolution (log-MAR)
for statistical analysis. To determine the equivalent mean
decimal, log-MAR values were converted back to decimal
notation [29].
Serial changes in BCVA, OCT, and central focal
thickness (CFT) were compared using the Wilcoxon
signed-rank test and two-tailed t-test. A p≤0.05 was
considered to be statistically significant.
These parameters were analyzed using SPSS statistical
software (version 16 for Mac OS X, SPSS Inc.).
Results
The study included 14 eyes of 14 patients. There were five
(36%) male and nine (64%) female patients. The mean
spherical equivalent refractive error was −12.5 (range, −8.0
D to −16.0 D). All eyes had retinal abnormalities consistent
with pathologic myopia, such as lacquer cracks. The mean
age of the patients was 59 years (range from 37 to 87 years);
50% of the patients were older than 61 years, and 50% were
younger than 58 years. Mean time of follow-up was
8.4 months (range from 3 to 16 months, SD: 3).
Angiographic features in all cases demonstrated classic
CNV. Seven eyes (50%) had previously received PDT.
CNV was subfoveal in 11 patients (79%) and juxtafoveal in
three (21%). The mean number of intravitreal injections
administered for each patient was 2.36 (SD 1.5). The mean
number of intravitreal injections administered concerning
the 11 patients that had a follow-up of at least 6 months
(mean 9.7 months, SD: 3) was 2.73 (SD 1.5). The mean
number of intravitreal injections administered concerning
the seven patients that had a follow-up of at least 9 months
(mean 11.4 months, SD: 2.4) was 2.71 (SD 1.7).
Visual acuity
The mean initial VA was 0.19 (decimal equivalent), with a
range from 0.06 to 0.5. Mean logMAR initial VA was 0.71
(SD: 0.3). A statistically significant improvement to a mean
VA of 0.48 decimal equivalent (logMAR 0.32, SD: 0.25)
was demonstrated at the final follow-up (p=0.001, Wil-
coxon signed-rank test). The VA improved by a mean of
3.86 (SD 2.74) lines. Nine patients (64%) demonstrated a
gain of 3 or more lines. Thirteen patients (93%) have
shown improvement of VA, while VA remained unchanged
in one patient. Table 1 shows the changes in mean BCVA
during the study.
Optical coherence tomography and fluorescein angiography
results
Mean CMT measured with OCT was 304 μm (SD: 39) at
baseline, and decreased significantly at the final follow-up
to 153 μm (SD: 23) (p<0.001, two-tailed t-test). Average
CMT reduction was 170 μm (SD: 57) (Fig. 1).
Table 1 shows the changes in mean OCT CMT during
this study. All eyes exhibited diminution or absence of
leakage on FA at the final follow-up (Figs. 2 and 3).
Patient age in this study appeared to have no influence in
a statistically significant way on VA improvement or
changes in mean OCT CMT.
Complications
No injection complications or drug-related side effects were
noted during the follow-up period.
Discussion
It has been shown that VEGF has an important role in
regulating angiogenesis and cell proliferation [30], and
therefore is related to the formation and regression of CNV
[31]. Tong et al. demonstrated that the levels of VEGF were
found to be significantly increased in the aqueous humor of
eyes with active CNV related to AMD and with CNV
related to PM [32], indicating that VEGF plays an
important role in the pathogenesis of CNV related to these
clinical conditions.
Ranibizumab is a recombinant humanized monoclonal
antibody fragment that inhibits the biologic activity of all
isoforms of human VEGF-A, and consequently leads to
Table 1 Best-corrected visual acuity (BCVA) and optical coherence tomographic parameters at baseline and each follow-up
Baseline
(14 eyes)
1 month
(14 eyes)
3 months
(14 eyes)
6 months
(11 eyes)
9 months
(7 eyes)
Final follow-up range
(3 to 16 months)
Mean decimal equivalent BCVA 0.19 0.36 0.43 0.43 0.41 0.48
log-MAR BCVA, mean ± SD 0.71 (0.30) 0.44 (0.26) 0.36 (0.25) 0.36 (0.27) 0.38 (0.33) 0.32 (0.25)
Mean macular thickness ± SDi 304 μm (39) 221 μm (50) 177 μm (26) 169 μm (20) 164 μm (19) 153 μm (23)
i log-MAR: logarithm of the minimum angle of resolution
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reductions in cell proliferation, vascular leakage, and
formation of new blood vessels [33]. Extensive, stringent,
multicenter, randomized clinical trials have shown that
ranibizumab provides significant VA benefit to patients
with all angiographic subtypes of CNV related to AMD
(i.e., minimally or predominantly classic or occult with no
classic component), with a low incidence of serious ocular
and non-ocular adverse events and an acceptable rate of
non-serious adverse events [17, 34, 35]. Furthermore,
ranibizumab was found to be superior to verteporfin for
treating predominantly classic CNV related to AMD [35].
On the evidence of these trials, the FDA approved
ranibizumab for the treatment of macular degeneration on
June 30 2006, after a priority review stating that ranibizu-
mab is the first treatment that can maintain the vision of
more than 90% of patients with wet AMD [36].
However, for subfoveal CNV related to PM, PDT with
verteporfin remains the only approved treatment. It is
nevertheless worth mentioning that the 2-year outcomes
of PDT in cases of subfoveal CNV associated with PM
failed to reveal a statistically significant treatment effect in
its primary outcome, the proportion of eyes with fewer than
8 letters of VA loss. In the trial, 36% of verteporfin-treated
eyes compared with 51% placebo-treated eyes had at least
an 8-letter loss in VA (p=0.11) [5].
Although there are no published studies regarding the
use of ranibizumab for the treatment of CNV in PM, several
studies have reported promising short-term results for the
treatment of CNV in PM with off-label use of the
intravitreal anti-VEGF drug bevacizumab; bevacizumab is
approved by the FDA for the treatment of colorectal cancer
[18–25].
Chan et al. treated 22 eyes for CNV secondary to PM
with intravitreal bevacizumab, reporting a visual mean
improvement of 2.6 lines and anatomic improvements
during 6 months of follow-up [18]. Hernandez-Rojas et al.
reported, in a study of 14 patients treated with intravitreal
bevacizumab for CNV secondary to PM, that foveal
thickness improved from 385.43±125.83 μm to 194.54±
54.35 μm after 3 months [19]. Mandal et al., in a case series
of 12 eyes, suggested that bevacizumab is a safe and
effective treatment for CNV secondary to PM, reporting an
average reduction of 174.25 μm of foveal thickness at
6 months. Yamamoto et al. treated 11 eyes with intravitreal
bevacizumab for CNV due to PM, achieving an average
reduction of 103 μm of foveal thickness and a mean VA
improvement of 3.5 lines after an average follow-up of
153 days.
In our study, a mean VA improvement of 3.86 lines (SD
2.74) was demonstrated after a mean follow-up of
Fig. 1 Baseline OCTs (a, c) showing hyper-reflectivity (1,2) under
the fovea due to the neovascular complex (1) with diffuse intraretinal
exudation (3,4). Last follow-up OCTs (b, d) showed a reduced
thickness of the neovascular complex with residual intraretinal cystic
exudation (5,6)
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8.4 months. Furthermore, an average reduction of 170 μm
(SD: 57) of foveal thickness was documented, and the mean
CNV size on FA was decreased significantly.
It is difficult to compare the different studies, consider-
ing the variability of the methodology, the follow-up, and
the re-treatment criteria of each study. Furthermore, the
visual results are much dependent on patient characteristics
like the duration of symptoms, age, CNV size and the pre-
treatment VA.
Ranibizumab, which is specifically formulated for
intraocular use [26], has several advantages over bevacizu-
mab. The primary molecular difference between these two
Fig. 2 a, b Baseline and last follow-up visit; color fundus photo-
graphs. c, d Early phase on baseline FA shows a well-defined
neovascular complex (1) in lacquer cracks, with significant exudation
(2) in the late phase. e, f On the last follow-up FA, there was a marked
reduction in size and exudation (3) of the neovascular membrane
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drugs is their molecular weight: ranibizumab is a 48-kD
Fab fragment, whereas bevacizumab is a complete 149-kD
antibody [37]. It has been demonstrated that ranibizumab
fully penetrates the retinal layers to the outer retina and
inner choroids, the pathophysiologic site of neovascular
AMD [38]. In an animal model, it was shown that a full-
length antibody [37] did not penetrate the inner limiting
membrane of the retina, in contrast to the Fab antibody
fragment that diffused through the neural retina to the
retinal pigment epithelial layer. Furthermore, ranibizumab
penetrates the retina faster than bevacizumab [27]. Fre-
quently, CNV due to PM is not associated with consider-
Fig. 3 g, h Baseline fundus photograph shows a subretinal hemor-
rhage (4) at the margin of the neovascular complex, which has
disappeared by the last follow-up. j Last follow-up FA shows a
marked reduction in size of the neovascular complex (5). k, l Late
phase of both initial and last follow-up FA showed mild leakage (6,7)
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able retinal edema; thus, retinal barriers might be less
disturbed in comparison to AMD cases, and thus a possible
higher penetration ability of the smaller molecule of
ranibizumab might be a significant advantage. Furthermore,
the ranibizumab active binding site reportedly has a greater
affinity to VEGF-A than bevacizumab, through a process of
affinity maturation [39]. In addition, ranibizumab could
theoretically be associated with fewer potential systemic
risks, given findings with systemic pharmacokinetics
suggesting that it is cleared much more rapidly from the
serum than bevacizumab [40].
One potential risk that should be considered in the
treatment of myopic CNVs with anti-VEGF, which has
been revealed in a recent study, is the possible formation
of marginal crack lines after treatment-related contraction of
the myopic CNVs, which was considered an indication of
early damage of retinal pigment epithelium that might lead
to expanding macular chorioretinal atrophy [41].
In conclusion, in this small series of eyes with limited
follow-up, intravitreal ranibizumab seems to be a safe and
effective treatment for CNV secondary to PM, resulting in
functional and anatomic improvements. The limitations of
this study include its small number of eyes, the relatively
short follow-up, and the absence of a control group. One
should consider that many treatments including PDT with
verteporfin, even if they have shown a beneficial effect in
the short term, failed to show significantly favourable
results in the long term. Various reasons can compromise
the long-term results, including progressive chorioretinal
atrophy or treatment-related cumulative, damage to the
photoreceptors and underlying retinal pigment epithelium,
as hypothesized in the VIP study [5].
In view of the encouraging results from this prospective
study, we consider that randomized, long-term clinical trials
are needed to determine more accurately the potential
clinical benefit of intravitreal ranibizumab and its safety.
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